Superpower peptides available for pre-order. Get first access.

Not FDA-approved

Digestive & weight

KPV

Also called lysine-proline-valine (α-MSH 11-13)

EvidenceLimited research
ClassAnti-inflammatory tripeptide

KPV is a three-amino-acid alpha-MSH fragment studied for inflammation. Evidence is animal and cell-based, with no human efficacy trials. It is not FDA-approved.

Reviewed by
William Maish, MD MBA MPH, Clinical Product Lead
Published
October 5, 2026
Last updated
October 29, 2026

Key takeaway

KPV is a small anti-inflammatory peptide derived from the tail of the hormone alpha-MSH, sold on the "research peptide" market for gut and skin inflammation. Its evidence is preclinical, with no human efficacy trials. As of October 2026 it is still not FDA-approved, but the FDA has granted enforcement discretion allowing it to be compounded by 503A pharmacies while formal rulemaking remains pending.

At a glance

FDA statusNon-FDA-approved peptide sold in the wellness/gray market
What it isThree-amino acid fragment of alpha-MSH with anti-inflammatory activity in lab models
ResearchEvidence is animal and cell-based only; there are no human efficacy trials
Compounding statusCompoundable by 503A pharmacies under FDA enforcement discretion since October 28, 2026, pending formal rulemaking; still not FDA-approved
Evidence strengthLimited research

What is KPV?

KPV is a tripeptide (lysine-proline-valine) corresponding to the tail end of alpha-MSH, a hormone with anti-inflammatory properties. It is sold through wellness and "research peptide" channels for gut inflammation, inflammatory bowel conditions, and skin, and it is not an approved medicine.

How does it work?

KPV retains much of alpha-MSH's anti-inflammatory activity. In laboratory models it is taken up into gut and immune cells, where it is proposed to reduce pro-inflammatory signaling, including the NF-kB pathway and downstream inflammatory messengers such as TNF-alpha. Notably, some of its anti-inflammatory activity appears independent of the MC1R receptor. These are cell and animal findings. This describes the proposed mechanism, separate from demonstrated benefit in people.

Is it FDA-approved?

No. KPV is not approved by the FDA. In July 2026 the FDA's Pharmacy Compounding Advisory Committee gave KPV a non-binding favorable vote toward the 503A compounding list. On October 28, 2026, the FDA granted enforcement discretion4 allowing 503A pharmacies to compound KPV (along with five other peptides) while the formal rulemaking to add it to the 503A bulks list is still pending. This permits licensed pharmacies to compound KPV, but it is not the same as FDA approval, it carries no stated end date, and it does not reflect any new finding that KPV is safe or effective.

What does the research show?

The evidence is preclinical. According to PubMed, two mouse studies of colitis reported these results:

Form testedModelFinding
KPVMouse models of colitisReduced inflammation, partly independent of MC1R (here1)
Nanoparticle-delivered KPVMice with colitisEased colitis, with mucosal healing and reduced TNF-alpha (here2)

Its anti-inflammatory basis is reviewed here3. There are no controlled human trials establishing KPV for gut or skin use, so its marketed benefit is unproven in people.

More for digestive & weight

Sources: mouse colitis studies of KPV (Kannengiesser et al., Inflammatory Bowel Diseases, 2008, DOI: 10.1002/ibd.203341; Xiao et al., Molecular Therapy, 2017, DOI: 10.1016/j.ymthe.2016.11.0202) and a review of alpha-MSH peptides (Luger and Brzoska, Annals of the Rheumatic Diseases, 2007, DOI: 10.1136/ard.2007.0797803), all indexed on PubMed; and reporting on the July 2026 FDA advisory committee vote. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.